Low vaccination and infection rate of Omicron in patients with inflammatory bowel disease: a comparative study of three unique cohorts
BackgroundThe SARS-CoV-2 Omicron variant caused a large-scale outbreak of COVID-19 in Shanghai, China. Patients with inflammatory bowel disease (IBD) are at high risk of infection due to immunosuppressive interventions. We aimed to investigate the vaccination information of patients with IBD and upd...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2023.1115127/full |
| _version_ | 1797803763202785280 |
|---|---|
| author | Jing Feng Tian Yang Ruchen Yao Bo Feng Bo Feng Renshan Hao Renshan Hao Yuqi Qiao Jinlu Tong Jun Shen Jun Shen |
| author_facet | Jing Feng Tian Yang Ruchen Yao Bo Feng Bo Feng Renshan Hao Renshan Hao Yuqi Qiao Jinlu Tong Jun Shen Jun Shen |
| author_sort | Jing Feng |
| collection | DOAJ |
| description | BackgroundThe SARS-CoV-2 Omicron variant caused a large-scale outbreak of COVID-19 in Shanghai, China. Patients with inflammatory bowel disease (IBD) are at high risk of infection due to immunosuppressive interventions. We aimed to investigate the vaccination information of patients with IBD and update a vaccination guide based on a comparison of vaccination in asymptomatic carriers and healthy individuals.MethodsThis retrospective study was conducted during an Omicron variant wave. We assessed the vaccination status in patients with IBD, asymptomatic carriers and healthy individuals. Factors with unvaccinated status and adverse events following vaccination were also determined in patients with IBD.ResultsThe vaccination rate was 51.2% in patients with IBD, 73.2% in asymptomatic carriers, and 96.1% in healthy individuals. Female sex (p = 0.012), Crohn’s disease (p = 0.026), and disease behavior of B3 (p = 0.029) were factors that indicated a lower vaccination rate. A significantly higher proportion of healthy individuals had received one booster dose (76.8%) than asymptomatic carriers (43.4%) and patients with IBD (26.2%). Patients with IBD received vaccination without an increased risk of adverse events (p = 0.768).ConclusionThe vaccination rate of patients with IBD remains much lower than that of asymptomatic carriers and healthy individuals. The COVID-19 vaccine has been found to be safe among all three groups and patients with IBD are not more susceptible to adverse events. |
| first_indexed | 2024-03-13T05:26:55Z |
| format | Article |
| id | doaj.art-e86e8f0524e64813a7b8c1fc518bf36c |
| institution | Directory Open Access Journal |
| issn | 2296-2565 |
| language | English |
| last_indexed | 2024-03-13T05:26:55Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj.art-e86e8f0524e64813a7b8c1fc518bf36c2023-06-15T05:51:37ZengFrontiers Media S.A.Frontiers in Public Health2296-25652023-06-011110.3389/fpubh.2023.11151271115127Low vaccination and infection rate of Omicron in patients with inflammatory bowel disease: a comparative study of three unique cohortsJing Feng0Tian Yang1Ruchen Yao2Bo Feng3Bo Feng4Renshan Hao5Renshan Hao6Yuqi Qiao7Jinlu Tong8Jun Shen9Jun Shen10Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Inflammatory Bowel Disease Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Inflammatory Bowel Disease Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Inflammatory Bowel Disease Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Respirology, Baoshan Branch, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Internal Medicine, Meipu Temporary Hospital, Shanghai, ChinaDepartment of Internal Medicine, Meipu Temporary Hospital, Shanghai, ChinaDepartment of Gastroenterology, Baoshan Branch, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Inflammatory Bowel Disease Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Inflammatory Bowel Disease Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Inflammatory Bowel Disease Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Internal Medicine, Meipu Temporary Hospital, Shanghai, ChinaBackgroundThe SARS-CoV-2 Omicron variant caused a large-scale outbreak of COVID-19 in Shanghai, China. Patients with inflammatory bowel disease (IBD) are at high risk of infection due to immunosuppressive interventions. We aimed to investigate the vaccination information of patients with IBD and update a vaccination guide based on a comparison of vaccination in asymptomatic carriers and healthy individuals.MethodsThis retrospective study was conducted during an Omicron variant wave. We assessed the vaccination status in patients with IBD, asymptomatic carriers and healthy individuals. Factors with unvaccinated status and adverse events following vaccination were also determined in patients with IBD.ResultsThe vaccination rate was 51.2% in patients with IBD, 73.2% in asymptomatic carriers, and 96.1% in healthy individuals. Female sex (p = 0.012), Crohn’s disease (p = 0.026), and disease behavior of B3 (p = 0.029) were factors that indicated a lower vaccination rate. A significantly higher proportion of healthy individuals had received one booster dose (76.8%) than asymptomatic carriers (43.4%) and patients with IBD (26.2%). Patients with IBD received vaccination without an increased risk of adverse events (p = 0.768).ConclusionThe vaccination rate of patients with IBD remains much lower than that of asymptomatic carriers and healthy individuals. The COVID-19 vaccine has been found to be safe among all three groups and patients with IBD are not more susceptible to adverse events.https://www.frontiersin.org/articles/10.3389/fpubh.2023.1115127/fullOmicronsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)coronavirus disease-19 (COVID-19)inflammatory bowel disease (IBD)asymptomatic |
| spellingShingle | Jing Feng Tian Yang Ruchen Yao Bo Feng Bo Feng Renshan Hao Renshan Hao Yuqi Qiao Jinlu Tong Jun Shen Jun Shen Low vaccination and infection rate of Omicron in patients with inflammatory bowel disease: a comparative study of three unique cohorts Frontiers in Public Health Omicron severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus disease-19 (COVID-19) inflammatory bowel disease (IBD) asymptomatic |
| title | Low vaccination and infection rate of Omicron in patients with inflammatory bowel disease: a comparative study of three unique cohorts |
| title_full | Low vaccination and infection rate of Omicron in patients with inflammatory bowel disease: a comparative study of three unique cohorts |
| title_fullStr | Low vaccination and infection rate of Omicron in patients with inflammatory bowel disease: a comparative study of three unique cohorts |
| title_full_unstemmed | Low vaccination and infection rate of Omicron in patients with inflammatory bowel disease: a comparative study of three unique cohorts |
| title_short | Low vaccination and infection rate of Omicron in patients with inflammatory bowel disease: a comparative study of three unique cohorts |
| title_sort | low vaccination and infection rate of omicron in patients with inflammatory bowel disease a comparative study of three unique cohorts |
| topic | Omicron severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus disease-19 (COVID-19) inflammatory bowel disease (IBD) asymptomatic |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2023.1115127/full |
| work_keys_str_mv | AT jingfeng lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts AT tianyang lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts AT ruchenyao lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts AT bofeng lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts AT bofeng lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts AT renshanhao lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts AT renshanhao lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts AT yuqiqiao lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts AT jinlutong lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts AT junshen lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts AT junshen lowvaccinationandinfectionrateofomicroninpatientswithinflammatoryboweldiseaseacomparativestudyofthreeuniquecohorts |